New knowledge for omarigliptin tablets: dissolution assay -behavior in different media and biopharmaceutical classification
DOI:
https://doi.org/10.22456/2527-2616.136825Keywords:
Omarigliptin, Dissolution assay, Solubility, Biopharmaceutical classification, ValidationAbstract
Omarigliptin (OMG) is an active substance for the treatment of type 2 diabetes and it is representing of the dipeptidyl peptidase IV inhibitors class, an important enzyme in the regulation of blood glucose. It was launched on the Japanese market in 2015 as a weekly dose innovation. This work aimed to report the results obtained of the OMG tablets solubilization in different media, evaluate the dissolution profiles in the chosen media, propose the biopharmaceutical classification, in addition to validate the dissolution method. After solubility test, the dissolution assay was conducted and a rapid process of tablets disintegration and dissolution was observed in three media having different pH values, they were acid hydrochloric 0.01M at pH 3.1, sodium acetate buffer at pH 4.5 and potassium phosphate buffer at pH 6.8. The potassium phosphate buffer medium was chosen to proceed with the dissolution method validation. With the profiles obtained in the three tested media it was possible to conclude that the dissolution is very fast, with 100% of the active substance dissolved in less than 10 min for all tested media. In addition, with the evaluation of the dissolution profile obtained in this work and data available in the literature, it was possible to suggest that OMG belongs to class I of the biopharmaceutical classification system. The proposed method was validated and contained all the necessary parameters recommended by the official guides.
Downloads
References
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-2157. Available from: https://doi.org/10.1053/j.gastro.2007.03.054
Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014; 57: 3205–3212. Available from: https://doi.org/10.1021/jm401992e
Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Barranco RJ, Umpierrez GE. Safety and efficacy of DPP4 inhibitor and basal insulin in type 2 diabetes: an updated review and challenging clinical scenarios. Diabetes Therapy. 2018; 9: 1775-1789. Available from: https://doi.org/10.1007/s13300-018- 0488-z
Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. Medicine, 2018; 97. Available from: https://doi.org/ 10.1097/MD.0000000000011946
Food and Drug Administration (FDA). Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General Considerations. Guidance for Industry. Available from: < https://www.fda.gov/files/drugs/published/Bioavailabi lity-and-Bioequivalence-Studies-Submitted-in-NDAsor-INDs-%E2%80%94-General-Considerations.pdf>
Grady H, Elder D, Webster GK, Mao Y, Lin Y, Flanagan T, et al. Industry's view on using quality control, biorelevant, and clinically relevant dissolution tests for pharmaceutical development, registration, and commercialization. Journal of Pharmaceutical Sciences. 2018; 107: 34-41. Available from: https://doi.org/10.1016/j.xphs.2017.10.019
Shekunov B, Montgomery ER. Theoretical analysis of drug dissolution: I. Solubility and intrinsic dissolution rate. Journal of Pharmaceutical Sciences. 2016; 105: 2685-2697. Available from: https://doi.org/10.1016/j.xphs.2015.12.006
Ayoub BM, Mowaka S, Arafa MG. Factorial design optimization of micelle enhanced synchronous spectrofluorimetric assay of Omarigliptin: Applied to content uniformity testing and in vitro drug release. Luminescence. 2018; 33: 797-805. Available from: https://doi.org/10.1002/bio.3479
International Conference on Harmonization (ICH). Harmonized Tripartite Guideline. Text on Validation of Analytical Procedures, Text and Methodology, Q2 (R1), Geneva; 2005.
Emanuelli J, Schapoval EES. Stability-indicating HPLC method for estimation of Omarigliptin in tablets–oxidative and photolytic kinetics and degradation products formed under oxidative conditions. Microchemical Journal. 2020; 157: 105084. Available from: https://doi.org/10.1016/j.microc.2020.105084
Agência Nacional de Vigilância Sanitária (BR). Resolução RDC n° 31 de 11 de agosto de 2010. Dispõe sobre a realização dos Estudos de Equivalência Farmacêutica e de Perfil de Dissolução Comparativo. Brasília, DF: Diário Oficial da União; 2010. Portuguese.
Xu S, Tatosian D, Mcintosh I, Caceres M, Matthews C, Samuel K. Absorption, metabolism and excretion of [14C] omarigliptin, a once-weekly DPP-4 inhibitor, in humans. Xenobiotica. 2018; 48: 584-591. Available from: https://doi.org/10.1080/00498254.2017.1346333
Li MF, Hu XX, Ma AQ. Ultra‐high pressure liquid chromatography–tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats. Biomedical Chromatography. 2017; 31: e3975. Available from: https://doi.org/10.1002/bmc.3975
Amidon GL, Lennernas H, Shah VP, Crison JP. A theoretical basis for a biopharmaceutics drug classification: The correlation on in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 1995; 12: 413- 420. Available from:
Agência Nacional de Vigilância Sanitária (BR). Guia de dissolução aplicável a medicamentos genéricos, novos e similares. Available from: http://portal.anvisa.gov.br/documents/10181/3364628/Proposta+de+Guia+de+Dissolu%C3%A7%C3%A3o+-+06.04.2018.pdf/c15476e5-82aa-402f-aa95-24bf246dccc0?version=1.0
Downloads
Published
Versions
- 26-03-2026 (2)
- 15-01-2024 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Drug Analytical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Licensing:
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.
